Diadema Partners’s Definium Therapeutics DFTX Stock Holding History

Diadema Partners’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$727K	Buy	+15,451	New	+$382K	0.09%	111
2025 Q4	–	Sell	-105,891	Closed	-$1.25M	–	170
2025 Q3	$1.25M	Sell	105,891 -52,645	-33%	-$491K	0.32%	79
2025 Q2	$1.03M	Buy	+158,536	New	+$1.04M	0.31%	61
2025 Q1	–	Sell	-4,710	Closed	-$32.8K	–	140
2024 Q4	$32.8K	Buy	+4,710	New	+$32.4K	0.01%	101

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Diadema Partners's DFTX Position: Q2 2026 in Review

Diadema Partners opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 15,451 shares worth $727K. The stake represents 0.09% of the portfolio and ranks #111 among its holdings. This is a return to the name: Diadema Partners previously reported a position in DFTX as recently as Q3 2025.

Diadema Partners first reported a position in DFTX in Q4 2024 and has held it in 4 quarters since. The position peaked at $1.25M in Q3 2025. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Diadema Partners held 15,451 shares of Definium Therapeutics worth $727K as of Q2 2026.
Definium Therapeutics was a new Diadema Partners position in Q2 2026.
Definium Therapeutics made up 0.09% of Diadema Partners's portfolio in Q2 2026, its #111 holding.
Diadema Partners first reported a position in Definium Therapeutics in Q4 2024 and has held it in 4 quarters since.
Diadema Partners's Definium Therapeutics position peaked at $1.25M in Q3 2025.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.